Cogent Biosciences, Inc. (COGT)
$31.00+3.06%Close
SELLRECOVERY · day 11
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $5.3B
- Beta
- 0.32
- P/E (TTM)
- -13.15
- Short % float
- 13.10%
- Days to cover
- 8.1
- SI change
- +7.4%
- 1W
- -0.06%
- 1M
- -9.04%
- vs SPY 1W
- -1.22%
- vs SPY 1M
- -12.03%
Industry peers
FMP comparable companies · ranked by market cap
- INCYSELLIncyte Corporation$22.9BBEARQ 13$112.79+0.04%
- TNGXSELLTango Therapeutics, Inc.$3.9BRECOVERYQ 24$23.81+5.49%
- IDYASELLIDEAYA Biosciences, Inc.$3.4BBEARQ 25$36.11+0.14%
- RCUSSELLArcus Biosciences, Inc.$3.1BRECOVERYQ 17$24.41+2.43%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.35+0.63%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.5BCRISISQ 17$16.99+0.53%
- MAZEBUYMaze Therapeutics, Inc.$1.5BRECOVERYQ 36$27.11+4.75%
- KURASELLKura Oncology, Inc.$941MBEARQ 12$10.60+0.76%
- AVBPSELLArriVent BioPharma, Inc.$779MCRISISQ -5$16.73+0.12%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on COGT?
- LOPJLB’s latest quantitative signal on Cogent Biosciences, Inc. (COGT) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is COGT in?
- Cogent Biosciences, Inc. (COGT) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Cogent Biosciences, Inc. (COGT) do?
- Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from…